| Dr Kobina Arhin Wilmot, MD | |
|
134 Medical Park Rd Ste 200, Mooresville, NC 28117-8527 | |
| (980) 302-7800 | |
| (980) 302-7805 |
| Full Name | Dr Kobina Arhin Wilmot |
|---|---|
| Gender | Male |
| Speciality | Cardiovascular Disease (cardiology) |
| Experience | 14 Years |
| Location | 134 Medical Park Rd Ste 200, Mooresville, North Carolina |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1356667505 | NPI | - | NPPES |
| 068577 | Other | GA | GEORGIA LICENSE NUMBER |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207R00000X | Internal Medicine | 2017-01391 (North Carolina) | Secondary |
| 207RC0000X | Internal Medicine - Cardiovascular Disease | 2017-01391 (North Carolina) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Novant Health Huntersville Medical Center | Huntersville, NC | Hospital |
| Novant Health Presbyterian Medical Center | Charlotte, NC | Hospital |
| Novant Health Matthews Medical Center | Matthews, NC | Hospital |
| Novant Health Rowan Medical Center | Salisbury, NC | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| The Presbyterian Hospital | 1153231907 | 359 |
| Novant Medical Group Inc | 1153234893 | 1996 |
News Archive
Patients with a specific kind of lung cancer may benefit from a Phase III clinical trial offered by the Moores UCSD Cancer Center. The new drug, crizotinib, under development by Pfizer, showed dramatic results in reducing lung cancer tumors in some patients during Phase I and II clinical trials.
Icotinib has been found to be noninferior to gefitinib in patients with non-small-cell lung cancer, according to reports from the phase III Chinese double-blind ICOGEN study.
Trevena, Inc., a clinical stage biopharmaceutical company and the leader in the discovery of G protein coupled receptor (GPCR) biased ligands, today announced the publication of its Phase 1b data for TRV130 in the journal Pain.
Scientists at the University of Cambridge have identified a new property of essential proteins which, when it malfunctions, can cause the build up, or 'aggregation', of misshaped proteins and lead to serious diseases.
› Verified 2 days ago
| Entity Name | Novant Medical Group Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1366409492 PECOS PAC ID: 1153234893 Enrollment ID: O20031121000692 |
News Archive
Patients with a specific kind of lung cancer may benefit from a Phase III clinical trial offered by the Moores UCSD Cancer Center. The new drug, crizotinib, under development by Pfizer, showed dramatic results in reducing lung cancer tumors in some patients during Phase I and II clinical trials.
Icotinib has been found to be noninferior to gefitinib in patients with non-small-cell lung cancer, according to reports from the phase III Chinese double-blind ICOGEN study.
Trevena, Inc., a clinical stage biopharmaceutical company and the leader in the discovery of G protein coupled receptor (GPCR) biased ligands, today announced the publication of its Phase 1b data for TRV130 in the journal Pain.
Scientists at the University of Cambridge have identified a new property of essential proteins which, when it malfunctions, can cause the build up, or 'aggregation', of misshaped proteins and lead to serious diseases.
› Verified 2 days ago
| Entity Name | Novant Medical Group Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1306950282 PECOS PAC ID: 1153234893 Enrollment ID: O20040204001028 |
News Archive
Patients with a specific kind of lung cancer may benefit from a Phase III clinical trial offered by the Moores UCSD Cancer Center. The new drug, crizotinib, under development by Pfizer, showed dramatic results in reducing lung cancer tumors in some patients during Phase I and II clinical trials.
Icotinib has been found to be noninferior to gefitinib in patients with non-small-cell lung cancer, according to reports from the phase III Chinese double-blind ICOGEN study.
Trevena, Inc., a clinical stage biopharmaceutical company and the leader in the discovery of G protein coupled receptor (GPCR) biased ligands, today announced the publication of its Phase 1b data for TRV130 in the journal Pain.
Scientists at the University of Cambridge have identified a new property of essential proteins which, when it malfunctions, can cause the build up, or 'aggregation', of misshaped proteins and lead to serious diseases.
› Verified 2 days ago
| Entity Name | The Presbyterian Hospital |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1053365817 PECOS PAC ID: 1153231907 Enrollment ID: O20040223001121 |
News Archive
Patients with a specific kind of lung cancer may benefit from a Phase III clinical trial offered by the Moores UCSD Cancer Center. The new drug, crizotinib, under development by Pfizer, showed dramatic results in reducing lung cancer tumors in some patients during Phase I and II clinical trials.
Icotinib has been found to be noninferior to gefitinib in patients with non-small-cell lung cancer, according to reports from the phase III Chinese double-blind ICOGEN study.
Trevena, Inc., a clinical stage biopharmaceutical company and the leader in the discovery of G protein coupled receptor (GPCR) biased ligands, today announced the publication of its Phase 1b data for TRV130 in the journal Pain.
Scientists at the University of Cambridge have identified a new property of essential proteins which, when it malfunctions, can cause the build up, or 'aggregation', of misshaped proteins and lead to serious diseases.
› Verified 2 days ago
| Entity Name | Novant Health Rowan Medical Center Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1508931544 PECOS PAC ID: 3375452519 Enrollment ID: O20040422001655 |
News Archive
Patients with a specific kind of lung cancer may benefit from a Phase III clinical trial offered by the Moores UCSD Cancer Center. The new drug, crizotinib, under development by Pfizer, showed dramatic results in reducing lung cancer tumors in some patients during Phase I and II clinical trials.
Icotinib has been found to be noninferior to gefitinib in patients with non-small-cell lung cancer, according to reports from the phase III Chinese double-blind ICOGEN study.
Trevena, Inc., a clinical stage biopharmaceutical company and the leader in the discovery of G protein coupled receptor (GPCR) biased ligands, today announced the publication of its Phase 1b data for TRV130 in the journal Pain.
Scientists at the University of Cambridge have identified a new property of essential proteins which, when it malfunctions, can cause the build up, or 'aggregation', of misshaped proteins and lead to serious diseases.
› Verified 2 days ago
| Entity Name | Novant Health Matthews Medical Center Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1184782419 PECOS PAC ID: 6406845247 Enrollment ID: O20051114000445 |
News Archive
Patients with a specific kind of lung cancer may benefit from a Phase III clinical trial offered by the Moores UCSD Cancer Center. The new drug, crizotinib, under development by Pfizer, showed dramatic results in reducing lung cancer tumors in some patients during Phase I and II clinical trials.
Icotinib has been found to be noninferior to gefitinib in patients with non-small-cell lung cancer, according to reports from the phase III Chinese double-blind ICOGEN study.
Trevena, Inc., a clinical stage biopharmaceutical company and the leader in the discovery of G protein coupled receptor (GPCR) biased ligands, today announced the publication of its Phase 1b data for TRV130 in the journal Pain.
Scientists at the University of Cambridge have identified a new property of essential proteins which, when it malfunctions, can cause the build up, or 'aggregation', of misshaped proteins and lead to serious diseases.
› Verified 2 days ago
| Entity Name | Moses Cone Affiliated Physicians, Inc. |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1346474103 PECOS PAC ID: 3779635396 Enrollment ID: O20090713000512 |
News Archive
Patients with a specific kind of lung cancer may benefit from a Phase III clinical trial offered by the Moores UCSD Cancer Center. The new drug, crizotinib, under development by Pfizer, showed dramatic results in reducing lung cancer tumors in some patients during Phase I and II clinical trials.
Icotinib has been found to be noninferior to gefitinib in patients with non-small-cell lung cancer, according to reports from the phase III Chinese double-blind ICOGEN study.
Trevena, Inc., a clinical stage biopharmaceutical company and the leader in the discovery of G protein coupled receptor (GPCR) biased ligands, today announced the publication of its Phase 1b data for TRV130 in the journal Pain.
Scientists at the University of Cambridge have identified a new property of essential proteins which, when it malfunctions, can cause the build up, or 'aggregation', of misshaped proteins and lead to serious diseases.
› Verified 2 days ago
| Entity Name | The Moses H Cone Memorial Hospital Operating Corporation |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1013265909 PECOS PAC ID: 6204744600 Enrollment ID: O20121003000518 |
News Archive
Patients with a specific kind of lung cancer may benefit from a Phase III clinical trial offered by the Moores UCSD Cancer Center. The new drug, crizotinib, under development by Pfizer, showed dramatic results in reducing lung cancer tumors in some patients during Phase I and II clinical trials.
Icotinib has been found to be noninferior to gefitinib in patients with non-small-cell lung cancer, according to reports from the phase III Chinese double-blind ICOGEN study.
Trevena, Inc., a clinical stage biopharmaceutical company and the leader in the discovery of G protein coupled receptor (GPCR) biased ligands, today announced the publication of its Phase 1b data for TRV130 in the journal Pain.
Scientists at the University of Cambridge have identified a new property of essential proteins which, when it malfunctions, can cause the build up, or 'aggregation', of misshaped proteins and lead to serious diseases.
› Verified 2 days ago
| Entity Name | Dlp Western Carolina Physician Practices Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1609281641 PECOS PAC ID: 9032338975 Enrollment ID: O20140908002531 |
News Archive
Patients with a specific kind of lung cancer may benefit from a Phase III clinical trial offered by the Moores UCSD Cancer Center. The new drug, crizotinib, under development by Pfizer, showed dramatic results in reducing lung cancer tumors in some patients during Phase I and II clinical trials.
Icotinib has been found to be noninferior to gefitinib in patients with non-small-cell lung cancer, according to reports from the phase III Chinese double-blind ICOGEN study.
Trevena, Inc., a clinical stage biopharmaceutical company and the leader in the discovery of G protein coupled receptor (GPCR) biased ligands, today announced the publication of its Phase 1b data for TRV130 in the journal Pain.
Scientists at the University of Cambridge have identified a new property of essential proteins which, when it malfunctions, can cause the build up, or 'aggregation', of misshaped proteins and lead to serious diseases.
› Verified 2 days ago
| Entity Name | Novant Health Mint Hill Medical Center, Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1063910404 PECOS PAC ID: 8123374394 Enrollment ID: O20181018000540 |
News Archive
Patients with a specific kind of lung cancer may benefit from a Phase III clinical trial offered by the Moores UCSD Cancer Center. The new drug, crizotinib, under development by Pfizer, showed dramatic results in reducing lung cancer tumors in some patients during Phase I and II clinical trials.
Icotinib has been found to be noninferior to gefitinib in patients with non-small-cell lung cancer, according to reports from the phase III Chinese double-blind ICOGEN study.
Trevena, Inc., a clinical stage biopharmaceutical company and the leader in the discovery of G protein coupled receptor (GPCR) biased ligands, today announced the publication of its Phase 1b data for TRV130 in the journal Pain.
Scientists at the University of Cambridge have identified a new property of essential proteins which, when it malfunctions, can cause the build up, or 'aggregation', of misshaped proteins and lead to serious diseases.
› Verified 2 days ago
| Entity Name | Novant Health Ballantyne Medical Center Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1760190607 PECOS PAC ID: 4880065143 Enrollment ID: O20230518003163 |
News Archive
Patients with a specific kind of lung cancer may benefit from a Phase III clinical trial offered by the Moores UCSD Cancer Center. The new drug, crizotinib, under development by Pfizer, showed dramatic results in reducing lung cancer tumors in some patients during Phase I and II clinical trials.
Icotinib has been found to be noninferior to gefitinib in patients with non-small-cell lung cancer, according to reports from the phase III Chinese double-blind ICOGEN study.
Trevena, Inc., a clinical stage biopharmaceutical company and the leader in the discovery of G protein coupled receptor (GPCR) biased ligands, today announced the publication of its Phase 1b data for TRV130 in the journal Pain.
Scientists at the University of Cambridge have identified a new property of essential proteins which, when it malfunctions, can cause the build up, or 'aggregation', of misshaped proteins and lead to serious diseases.
› Verified 2 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dr Kobina Arhin Wilmot, MD Po Box 60447, Charlotte, NC 28260-0447 Ph: (980) 302-7800 | Dr Kobina Arhin Wilmot, MD 134 Medical Park Rd Ste 200, Mooresville, NC 28117-8527 Ph: (980) 302-7800 |
News Archive
Patients with a specific kind of lung cancer may benefit from a Phase III clinical trial offered by the Moores UCSD Cancer Center. The new drug, crizotinib, under development by Pfizer, showed dramatic results in reducing lung cancer tumors in some patients during Phase I and II clinical trials.
Icotinib has been found to be noninferior to gefitinib in patients with non-small-cell lung cancer, according to reports from the phase III Chinese double-blind ICOGEN study.
Trevena, Inc., a clinical stage biopharmaceutical company and the leader in the discovery of G protein coupled receptor (GPCR) biased ligands, today announced the publication of its Phase 1b data for TRV130 in the journal Pain.
Scientists at the University of Cambridge have identified a new property of essential proteins which, when it malfunctions, can cause the build up, or 'aggregation', of misshaped proteins and lead to serious diseases.
› Verified 2 days ago
Aileen Deng, Cardiovascular Disease Medicare: Accepting Medicare Assignments Practice Location: 170 Medical Park Rd Ste 101, Mooresville, NC 28117 Phone: 980-302-7070 Fax: 980-302-7075 | |
Laila Noor Menon, M.D. Cardiovascular Disease Medicare: Accepting Medicare Assignments Practice Location: 170 Medical Park Rd, Mooresville, NC 28117 Phone: 704-664-9506 | |
Patrick L. Fry, MD Cardiovascular Disease Medicare: Accepting Medicare Assignments Practice Location: 170 Medical Park Rd, Ste 140a, Mooresville, NC 28117 Phone: 704-663-4443 | |
Dr. Suraj Arora, M.D. Cardiovascular Disease Medicare: Accepting Medicare Assignments Practice Location: 134 Medical Park Rd Ste 200, Mooresville, NC 28117 Phone: 704-384-7972 Fax: 704-384-7973 | |
Richard Krumdieck, MD Cardiovascular Disease Medicare: Accepting Medicare Assignments Practice Location: 170 Medical Park Road, Ste 101, Mooresville, NC 28117 Phone: 704-799-3946 Fax: 704-799-3956 | |
Dr. Stephen Peter Stowe, M.D. Cardiovascular Disease Medicare: Not Enrolled in Medicare Practice Location: 603 East Center St, Suite A, Mooresville, NC 28115 Phone: 704-663-5090 Fax: 704-663-5502 | |
Dr. Smitha Reddy Pasula, M.D. Cardiovascular Disease Medicare: Accepting Medicare Assignments Practice Location: 930 W Wilson Ave, Mooresville, NC 28117 Phone: 704-663-7500 |